PharmaCorp Rx Inc.
PCRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -174.35% | -165.50% | -41.74% | 108.43% | 65.76% |
| Total Depreciation and Amortization | 94.86% | 134.62% | 222.56% | 684.86% | 2,700.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 242.33% | 219.85% | 160.72% | -158.04% | 2,616.67% |
| Change in Net Operating Assets | -2,249.17% | -291.20% | 204.60% | 919.30% | -95.57% |
| Cash from Operations | -46.36% | -292.44% | 1,964.12% | 221.62% | 151.44% |
| Capital Expenditure | 3,622.14% | 6,058.65% | 29,198.00% | 29,476.00% | -686.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 44.53% | 36.74% | 36.74% | -1,178.71% | -22,071.67% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -47.65% | -- | -- | -- | -- |
| Cash from Investing | 44.63% | 17.52% | 17.85% | -1,177.20% | -27,012.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -96.15% | -133.08% | -191.32% | -261.25% | -1,089.54% |
| Issuance of Common Stock | 180.76% | -22.02% | -22.02% | -88.50% | -61.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 232.02% | -10.04% | -11.34% | -89.34% | -62.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 218.75% | -9.33% | 15.59% | -188.08% | -161.93% |